ORYZON GENOMICS, S.A. «...678910...» Page 9 out of 12 13/10/2021 08:04 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents safety and efficacy data of vafidemstat from the Phase II SATEEN trial in multiple sclerosis at the ECTRIMS-2021 congress Register number: 12139 29/07/2021 17:51 ORYZON GENOMICS, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del primer semestre de 2021 Register number: 11043 13/07/2021 08:07 ORYZON GENOMICS, S.A. Other relevant information ORYZON receives approval from the Spanish Drug Agency to conduct a Phase IIb clinical trial with vafidemstat in schizophrenia patients. Register number: 10576 09/07/2021 08:01 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents preliminary data from vafidemstat’s Phase II trial ESCAPE in CoVID-19 patients at the 31st European Congress of Clinical Microbiology and Infectious Diseases, ECCMID-2021 Register number: 10551 15/06/2021 07:54 ORYZON GENOMICS, S.A. Other relevant information ORYZON receives FDA approval for its IND for PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder Register number: 9987 11/06/2021 08:06 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents new iadademstat’s ALICE Phase IIa data at EHA-2021, confirming positive and robust efficacy in combination with azacitidine in AML Register number: 9929 27/05/2021 07:21 ORYZON GENOMICS, S.A. Announcement of general shareholders’ meeting Call of the Ordinary General Shareholders’ Meeting of Oryzon Genomics, S.A. Register number: 9625 07/05/2021 17:47 ORYZON GENOMICS, S.A. Other relevant information La Sociedad remite información sobre los resultados del primer trimestre de 2021 Register number: 9305 12/04/2021 11:02 ORYZON GENOMICS, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 8517 09/03/2021 08:03 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the virtual AD/PD-2021 conference Register number: 7847 Page 9 out of 12 «...678910...»